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Screening Program, The Cancer Registry of Norway, Oslo, NorwayA B S T R A C TBackground: Decision makers often need to simultaneously consider
multiple criteria or outcomes when deciding whether to adopt new
health interventions. Objectives: Using decision analysis within the
context of cervical cancer screening in Norway, we aimed to aid decision
makers in identifying a subset of relevant strategies that are simulta-
neously efﬁcient, feasible, and optimal.Methods: We developed an age-
stratiﬁed probabilistic decision tree model following a cohort of women
attending primary screening through one screening round. We enum-
erated detected precancers (i.e., cervical intraepithelial neoplasia of
grade 2 or more severe (CIN2+)), colposcopies performed, and monetary
costs associated with 10 alternative triage algorithms for women with
abnormal cytology results. As efﬁciency metrics, we calculated incre-
mental cost-effectiveness, and harm-beneﬁt, ratios, deﬁned as the
additional costs, or the additional number of colposcopies, per addi-
tional CIN2þ detected. We estimated capacity requirements and uncer-
tainty surrounding which strategy is optimal according to the decisionee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.08.003
st: The authors have indicated that they have no
ersen@medisin.uio.no.
ndence to: Kine Pedersen, P.O. Box 1089, Blindern,rule, involving willingness to pay (monetary or resources consumed per
added beneﬁt). Results: For ages 25 to 33 years, we eliminated four
strategies that did not fall on either efﬁciency frontier, while one
strategy was efﬁcient with respect to both efﬁciency metrics. Compared
with current practice in Norway, two strategies detected more pre-
cancers at lower monetary costs, but some required more colposcopies.
Similar results were found for women aged 34 to 69 years. Conclusions:
Improving the effectiveness and efﬁciency of cervical cancer screening
may necessitate additional resources. Although efﬁcient and feasible,
both society and individuals must specify their willingness to accept the
additional resources and perceived harms required to increase effective-
ness before a strategy can be considered optimal.
Keywords: decision analysis, decision making, economic evaluation.
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Pharmacoeconomics and Outcomes Research (ISPOR).Background
The efﬁciency, feasibility, and optimality of new health inter-
ventions are important criteria that stakeholders often need to
consider simultaneously when choosing between multiple com-
peting strategies (e.g., alternative cancer screening algorithms).
Because it is often not feasible for clinical trials to evaluate all
possible aspects related to new health interventions, decision-
analytic modeling, an approach to provide epidemiologic projec-
tions and policy guidance, is gaining acceptance [1]. This quanti-
tative framework formally synthesizes available data and
explicitly incorporates decision uncertainty [2]. Analytic model-
ing can enumerate multiple outcomes of interest associated with
each candidate strategy, and it can easily be extended to evaluate
multiple epidemiologic and resource outcomes. Although it ismore common for decision analyses to examine the value of
alternative strategies in terms of monetary costs and quality-
adjusted life-years gained, evaluating resource use and harms
to patients has received less attention, but is often of interest
to decision makers. For example, alternative strategies often
involve multiple trade-offs such as surrogate endpoints in terms
of beneﬁts and harms to patients, as well as capacity requirements
in the health service delivery, whichmay help predict resource use
at different levels of the health system. These outcomes, however,
may help inform individual-level decision making (i.e., patients),
thus complementing cost-effectiveness analyses and ensuring the
viability of new health care interventions.
Recently, Norwegian decision makers, who were tasked with
improving the current organized cervical cancer screening pro-
gram, were interested in evaluating the impact of alternativeon behalf of International Society for Pharmacoeconomics and
conﬂicts of interest with regard to the content of this article.
0317 Oslo, Norway.
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number of colposcopy referrals. In Norway, current cervical
cancer prevention strategies include triennial Papanicolaou test
(cytology)-based screening, nationally organized since 1995, and a
school-based human papillomavirus (HPV) vaccination program
for 12-year-old girls since 2009. Nonetheless, cervical cancer
remains the third most common cancer among women aged 25
to 49 years [3], contributing to motivate decision makers to
evaluate alternative screening guidelines that could improve
screening program effectiveness. Following advances in cervical
cancer screening technology, Norwegian decision makers con-
sidered how to augment the current program by introducing
retesting of a woman’s initial cytology sample for HPV (called
reﬂex HPV testing), to guide the management of women with
atypical or low-grade cytology results (atypical squamous cells of
undetermined signiﬁcance [ASC-US] and low-grade squamous
intraepithelial lesion [LSIL]). Multiple stakeholders aimed to
maximize the detection of high-grade precancerous lesions
(i.e., cervical intraepithelial neoplasia of grade 2 or more severe
[CIN2þ]), while simultaneously keeping the number of required
consultations, losses to follow-up, and diagnostic tests (especially
colposcopies) with their associated harms and monetary costs at
an acceptable level. Furthermore, of particular interest to deci-
sion makers was what would happen within a single screening
round. In July 2014, an updated algorithm for the follow-up of
screen-positives using reﬂex HPV testing was implemented by
the Norwegian health authorities.
The health beneﬁts achieved by national screening programs,
in terms of reduced morbidity and mortality [4–6], demand health
care resources with an opportunity cost and involve potential
harms to patients throughout the screening process (screening
test, diagnostic test, and treatment). Although the evidence is
sparse, anxiety among both participants and nonparticipants
may result from invitation to the screening program and
subsequent diagnostic procedures as well as awaiting test results
[7–9]. Furthermore, diagnostic conﬁrmation of high-grade precur-
sors requires a semi-invasive procedure, that is, colposcopy-
directed biopsy, which may induce pain, bleeding, or discharge
[10]. If a high-grade precursor (CIN2þ) is detected, the woman is
advised to undergo conization, an excisional procedure usually
performed under local anesthesia, with associated adverse
effects such as bleeding, discomfort, and occasionally infections.
Conizations have also been associated with increased risk of late-
term abortions, preterm delivery, low birth weight, and cesarean
section [11,12]. Moreover, population-based screening results in
some degree of overtreatment because most of those who
undergo conization would never develop invasive cervical cancer
[13]. It is unknown, however, both ex ante and ex post, which high-
grade lesions would progress to cancer or regress spontaneously,
and in the absence of more accurate progression markers,
generally all CIN2þ lesions are treated among women 25 years
and older. For women younger than 25 years with well-deﬁned
and visible precursor lesions, and during pregnancies, these
lesions can be followed up without immediate treatment because
of higher regression rates [14]. Screening and treatment guide-
lines must deal with a fundamental trade-off between the
potential harms and beneﬁts caused by the detection and
removal of high-grade lesions. Furthermore, increased effective-
ness may necessitate additional resources, requiring both avail-
able health care capacity and a willingness to pay the additional
resource costs, for the strategies to be viable and optimal.
Decision-analytic models have been previously applied to
cervical cancer screening in Norway and elsewhere [15–17];
however, investigating surrogate end points and resource use in
natural units has received less attention. Although traditional
cost-effectiveness analyses focus on the additional monetary
cost per additional (quality-adjusted) life-year gained, ouranalysis offers a more comprehensive investigation of outcomes
associated with candidate cervical cancer screening strategies. In
particular, we projected the short-term (i.e., through a single
screening round) monetary cost and required colposcopies per
additional precancer detected associated with alternative strat-
egies. Our objective was to provide Norwegian stakeholders with
a formal consequence analysis to isolate screening strategies that
were simultaneously efﬁcient, feasible, and optimal according to
a set of efﬁciency metrics.Methods
Analytical Approach
In a decision-making process, initial steps involve the identiﬁca-
tion of relevant candidate strategies, outcomes, and efﬁciency
metrics. We deﬁned strategies and outcomes in collaboration
with multiple stakeholders, including clinicians, economists, and
representatives of management and advisory groups of the
Norwegian Cervical Cancer Screening Program. We included
strategies that had been outlined by the stakeholders who were
tasked with improving the current screening program. To assist
the stakeholders to determine the optimal screening algorithm,
we deﬁned efﬁciency metrics according to their primary con-
cerns, namely, how these strategies would perform in terms of
precancer detection, colposcopy referrals, and total costs, within
one screening interval. Consequently, we deﬁned two efﬁciency
metrics. For our primary analysis, we conducted a harm-beneﬁt
analysis by calculating incremental harm-beneﬁt ratios (IHBRs),
deﬁned as the additional number of colposcopies required to
detect an additional CIN2þ compared with the next most “harm-
ful” strategy. In addition, we performed a cost-effectiveness
analysis and investigated the incremental cost-effectiveness
ratios (ICERs) in terms of additional costs per additional CIN2þ
detected of a strategy compared with the next most costly
strategy. To detect efﬁcient strategies, we ﬁrst excluded strategies
that resulted in higher harms/costs and lower beneﬁts than did
others (strongly dominated), or higher harms/costs per additional
beneﬁt compared with the next most harmful/costly strategy
(weakly dominated), and then calculated the IHBRs/ICERs for the
nondominated strategies. In the traditional cost-effectiveness
framework, a strategy is considered “good value for money,” or
cost-effective, if its ICER is below the value of the decision
threshold, that is, the willingness to pay for an additional unit
of the outcome (in this case, CIN2þ). In contrast to analyses in
which health beneﬁts are measured in life-years or quality-
adjusted life-years, there is no established threshold that con-
stitutes a reasonable relationship between costs and health
beneﬁts when measured in natural units, such as CIN2þ [18].
Similarly, there is no established benchmark for how many
additional colposcopies women are willing to accept for one
additional detected CIN2þ. Therefore, we explored the optimal
strategy as a function of the willingness-to-pay or willingness-to-
accept thresholds, depicted in harm-beneﬁt and cost-
effectiveness acceptability curves. Finally, because of capacity
constraints in Norwegian pathology laboratories, we investigated
the feasibility of the alternative strategies by calculating the
relative resource use (i.e., number of tests and colposcopies)
required by each strategy compared with the baseline strategy
(strategy 1).
We adopted a societal perspective, and we discounted costs
and health beneﬁts by 4% per year, consistent with Norwegian
guidelines for economic evaluations [19]. We incorporated
parameter uncertainty through probabilistic Monte-Carlo simu-
lation with 10,000 samples. In accordance with recommended
modeling practice [20], we assigned beta distributions to all
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result), proportions, and diagnostic test characteristics. We fur-
ther assigned gamma distributions to all cost parameters and
Poisson distributions to count variables. In line with “good
modeling practice” [21], we conﬁrmed the face validity of model
inputs, that is, clinical assumptions and epidemiologic data, with
Norwegian experts, to ensure model components are in accord-
ance with current knowledge. We validated the model internally
using an iterative approach involving cross-checking model
equations and inputs against their sources, in addition to using
TreeAge’s (2013) debugging and validation tools [22].
Model Overview and Screening Strategies
We developed a probabilistic decision tree model that simulated
a cohort of women from the initial screening test (index test)
through one screening round of follow-up (i.e., 3 years), using the
software TreeAge Pro 2014. We compared a baseline screening
strategy (i.e., the Norwegian screening algorithm used until July
2014 [strategy 1]) with nine alternative HPV-based triage strat-
egies (strategies 2–10) that varied the follow-up of women with
low-grade lesions and inadequate cytology results (Fig. 1 and
Table 1). The baseline strategy (strategy 1) involves primary
Papanicolaou test–based screening every 3 years. Women with
an ASC-US or LSIL result are triaged with repeat cytology in
combination with HPV test 6 to 12 months after the initial test. In
contrast, all alternative strategies involve reﬂex HPV testing in
triage of women with ASC-US or LSIL, that is, using the same
specimen from the cytologic test to analyze for high-risk HPVFig. 1 – Overview of screening strategies. We compared the guide
alternative strategies (lower panel). For the baseline strategy, wom
triaged with a repeat cytology in combination with an HPV test in 1
ASC-H, atypical squamous cells, cannot rule out high-grade lesion;
HSIL, high-grade squamous intraepithelial lesion; HPV, human patypes, followed by workup according to the cytology/HPV result.
We also investigated the added value of applying a reﬂex HPV
test to inadequate cytology results versus repeat cytology in 3
months. One of the alternative strategies, strategy 10, represents
the recently implemented strategy in Norway as of July 2014,
hereafter referred to as the recent strategy (Fig. 1).
For all analyses, we maintained the 3-year screening interval
and kept workup for women with high-grade cytology results
(atypical squamous cells, cannot rule out high-grade lesion/high-
grade squamous intraepithelial lesion) constant. To account for
the likely switch to primary HPV testing for women aged 34 to 69
years following an implementation study slated to begin in the
ﬁrst half of 2015, we stratiﬁed our analyses for women aged 25 to
33 and 34 to 69 years. To reﬂect the impact of compliance with
the optimal strategy, we assumed age- and referral-stratiﬁed loss
to follow-up per procedure (i.e., the risk that women with
abnormal screening results drop out of screening and do not
return) in line with observed Norwegian data (see Table I in
Supplemental Material found at http://dx.doi.org/10.1016/j.jval.
2015.08.003). Primary outcomes included the number of CIN2þ
detected and the number of colposcopy referrals per 100,000
screened women for each strategy. In addition, we estimated the
expected number of cytologic and HPV tests performed, the
number of physician consultations, and costs associated with
diagnostic testing and analysis, including time and travel costs
for women to attend screening. The Cancer Registry of Norway,
the University Hospital of North Norway, and Norwegian fee
schedules [23–25] were used to inform Norwegian-speciﬁc epi-
demiologic parameters and estimate screening costs. Wherelines in Norway until July 1, 2014 (upper panel), with nine
en with index cytology results indicating ASC-US or LSIL are
2months, with further follow-up according to the co-test result.
ASC-US, atypical squamous cells of undetermined signiﬁcance;
pillomavirus; LSIL, low-grade squamous intraepithelial lesion.
Table 1 – Overview of model strategies and their respective triage algorithm.
Strategy Algorithmic
combination*
Follow-up after
Reﬂex HPV test positive Reﬂex HPV test negative Index cytology
inadequate
Strategy 1 – Baseline strategy; screening guidelines in Norway until July 1, 2014
Strategy 2 1a 2a 3a Colposcopy w/biopsy Return to screening in 3 y New cytology in 3 mo
Strategy 3 1a 2a 3b Colposcopy w/biopsy Return to screening in 3 y Reﬂex HPV test
Strategy 4 1a 2b 3a Colposcopy w/biopsy Repeat HPV test in 12 mo for LSIL New cytology in 3 mo
Strategy 5 1a 2b 3b Colposcopy w/biopsy Repeat HPV test in 12 mo for LSIL Reﬂex HPV test
Strategy 6 1b 2a 3a Repeat HPV test in 12 mo Return to screening in 3 y New cytology in 3 mo
Strategy 7 1b 2a 3b Repeat HPV test in 12 mo Return to screening in 3 y Reﬂex HPV test
Strategy 8 1b 2b 3a Repeat HPV test in 12 mo Repeat HPV test in 12 mo for LSIL New cytology in 3 mo
Strategy 9 1b 2b 3b Repeat HPV test in 12 mo Repeat HPV test in 12 mo for LSIL Reﬂex HPV test
Strategy 10 1c 2a 3a Recently implemented strategy in Norway
HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; mo, months; y, years.
* Refers to the pathways depicted in Figure 1.
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using published literature and expert opinion.
Epidemiologic Data
We used data from The Cancer Registry of Norway for the
positivity rate of primary cytology as well as secondary screening
outcomes in our baseline strategy (Table 2). In addition, we used
data on the number of observed CIN2þ in Norway to calibrate the
baseline prevalence of CIN2þ at 3.3% for ages 25 to 33 years and
0.8% for ages 34 to 69 years (for additional information on the
calibration process, see Part 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.08.003). We extracted dataTable 2 – Key epidemiologic and cost data.
Data Value
Epidemiologic
Positivity rates (%)
Primary cytologic test
Ages 25–33 y 5.54
Ages 34–69 y 2.86
Reﬂex HPV test in triage of ASC-US/LSIL
Ages 25–33 y 58.33
Ages 34–69 y 37.26
Sensitivity for CIN2þ (%)
Sensitivity of liquid-based cytology 71.5
Sensitivity of HPV DNA test 90.0
Sensitivity of colposcopy/biopsy 76.2
Cost (US $)
Physician consultations
Cost of general practitioner visit 59
Cost of gynecologist visit 102
Cost of informing patient about test result 9
Laboratory costs of analyzing tests
Liquid-based cytology 48
HPV test 92
Biopsy 135
Patient time and travel costs
Time cost (per hour) 51
Travel cost (per consultation) 31
Note. Exchange rate: US $1 ¼ 6.35 NOK.
ASC-US, atypical squamous cells of undetermined signiﬁcance; CI, conﬁ
more severe; HPV, human papillomavirus; LSIL, low-grade squamous infrom cervical cancer clinical trials in Europe and the United
States in situations in which Norwegian data were not available
(see Part 1 in Supplementary Materials found at http://dx.doi.org/
10.1016/j.jval.2015.08.003). Because HPV testing has not yet been
performed in primary screening in Norway, we used data from
published literature as a proxy for expected positivity rates for
primary reﬂex HPV testing as well as subsequent follow-up
parameters (Table 2) [26–33].
Data on the natural history of disease and the accuracy of
screening diagnostics were derived from published literature [34–
46]. The model does not differentiate between HPV genotypes. In
addition, we did not allow for progression from “negative for
intraepithelial lesion or malignancy” or “cervical intraepithelial95% CI Reference
[24]
5.37–5.72
2.80–2.92
57.54–59.12 [26–29,31–33]
36.80–37.72 [26–30,32,33]
62.9–78.8 [34]
88.0–93.0 [35]
73.3–79.1 [37,45,46]
[23]
47–71
81–122
7–10
[23,50]
38–58
74–112
108–162
41–62 [51]
26–38 [52]
dence interval; CIN2þ ¼ cervical intraepithelial neoplasia grade 2 or
traepithelial lesion; NOK, Norwegian kroner.
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tive of the analysis. To reﬂect the natural course of CIN2þ,
however, we allowed precancerous lesions to regress to CIN1 or
no lesion. We also assumed that 49% of the HPV infections
regressed within 12 months [39,40,42–44], and we represented
the natural history of CIN2þ by a time-dependent monthly
regression rate (7% for the initial 12 months [38,41], and 2%
thereafter [36]). Finally, screening test characteristics and proba-
bility of regression of CIN2þ were based on published studies and
meta-analyses (Table 2). We assumed that the sensitivity of
liquid-based cytology was 71.5% (95% conﬁdence interval [CI]
62.9–78.8) [34], 90% (95% CI 88.0-93.0) [35] for HPV testing, and
76.2% (95% CI 73.3–79.1) for colposcopy with biopsy [37,45,46].
Cost Data
Cost data were obtained from a recently published cost analysis
of cervical cancer screening in Norway (Table 2) [47]. We identi-
ﬁed the following cost components in cervical cancer screening:
cost of general practitioner visit and gynecologist consultation
including information to patients about test result; laboratory
costs of analyzing liquid-based cytology, HPV test, and biopsy;
cost of performing colposcopy/biopsy at hospital or gynecologist;
and patient time and travel costs incurred by screening consul-
tations. Quantiﬁcation of consultations and procedures was
determined endogenously from the model on the basis of
enumeration of consultations and diagnostic tests performed.
We assumed, however, that a primary care test (cytology and/or
HPV test) and diagnostic colposcopy/biopsy would require 2 and 4
hours of the patient’s time, respectively. Direct medical costs
were valued on the basis of actual resource use in Norwegian
pathologic laboratories in addition to national fee schedules [48–
50]. Indirect costs included patient travel time in terms of
opportunity cost of work absenteeism, and travel costs. To
estimate the value of work absenteeism and of time, we used
the national wage rate data [51]. Finally, we used data on travel
costs from a previously published cost analysis of breast cancer
screening in Norway [52]. In line with our primary outcome of
detected CIN2þ, we excluded CIN2þ treatment costs from the
cost calculations. All costs were expressed in 2013 Norwegian
kroner and converted to US dollar (US $1 ¼ NOK6.35). We
captured uncertainty in costs using 20% the point estimate.
More information about cost calculations is available in Part 3 in
Supplementary Materials found at http://dx.doi.org/10.1016/j.jval.
2015.08.003.Results
Efﬁciency
For women aged 25 to 33 years, 7 of the 10 strategies were either
strongly or weakly dominated with respect to additional costs per
additional CIN2þ detected (Fig. 2). Of note, dominated strategies
included both the previous (strategy 1) and the newly imple-
mented (strategy 10) strategies. Among the strategies on the cost-
effectiveness efﬁciency frontier, the ICERs ranged from $1,922 to
$11,550 per CIN2þ detected (Table 3). With regard to beneﬁts and
harms, only six strategies were dominated and excluded from the
analysis (Fig. 2). For the remaining strategies on the harm-beneﬁt
efﬁciency frontier, the IHBRs ranged from 2.93 to 10.91 additional
colposcopies per additional precancer detected (Table 3). When
incorporating both cost-effectiveness and harm-beneﬁt out-
comes, only one strategy remained on the frontiers for both
efﬁciency metrics. Similar trends follow for women aged 34 to 69
years; results are presented in Part 4 in Supplementary Materials
found at http://dx.doi.org/10.1016/j.jval.2015.08.003.Feasibility
We evaluated the feasibility of each strategy on the efﬁciency
frontiers by estimating the relative resources required, in terms of
additional costs and colposcopies, compared with the baseline
strategy (strategy 1). The relative effectiveness, cost, and colposcopy
use for each strategy on the efﬁciency frontiers, compared with the
baseline strategy, are presented in Table 3. The strategy (strategy 5)
that was identiﬁed as efﬁcient by both cost-effectiveness and harm-
beneﬁt efﬁciency metrics provided more beneﬁts (36% increase in
CIN2þ detection) for similar use of monetary costs, but required
more colposcopies (66%) than did the baseline strategy. Strategies 7
and 3 projected a 1% and 32% increase in the number of CIN2þ
detected, while simultaneously reducing costs by 4% and 1%,
respectively. For the four strategies that were efﬁcient with respect
to colposcopy use (strategies 6, 8, 4, and 5), one strategy (strategy 8)
detected 2% more CIN2þ while simultaneously requiring 6% fewer
colposcopies. For strategies 4 and 5, 28% and 36% more precancers
could be detected at a cost of 47% and 66% more colposcopies,
compared with current guidelines, respectively. Consequently,
although strategy 8 provides an opportunity for a resource-saving
intervention, implementing strategies 4 and 5 would require addi-
tional colposcopy resources to be feasible. Moreover, the potential
increase in CIN2þ detection afforded by the efﬁcient strategies
require that health care resources for the treatment of detected
CIN2þ be available to be deemed viable.
Optimality and Uncertainty
The ICERs and IHBRs presented in Table 3 represent the threshold
value of a decision rule required for a strategy to be deemed
optimal, in terms of the willingness to pay ﬁnancially, and the
willingness to accept additional colposcopies per additional
detected precursor, respectively. Parameter uncertainty surround-
ing which strategy is optimal for given values of the decision rule
is presented in the cost-effectiveness and harm-beneﬁt accept-
ability curves (Fig. 3). As the willingness-to-pay and willingness-to-
accept values increase, the more effective strategies become
increasingly “cost-effective” in most of the iterations. For example,
the two most effective strategies in terms of CIN2þ detection,
strategies 4 and 5, were cost-effective in most of the iterations
given a willingness to accept 6 and 12 additional colposcopies per
additional CIN2þ detected, respectively. Furthermore, strategy 5
was cost-effective in most of the iterations given a willingness-to-
pay value of $12,000 per additional CIN2þ detected.Discussion
The results of our case example indicate that there is a potential for
improving the baseline screening algorithm by implementing reﬂex
HPV testing for women with inadequate or low-grade cytology
results, for both women aged 25 to 33 years and 34 to 69 years. Four
strategies were dominated with respect to either cost-effectiveness
or harm-beneﬁt outcomes and were excluded from consideration
and further analyses. Among the efﬁcient strategies, the incremen-
tal cost-effectiveness and harm-beneﬁt ratios were closely related
because colposcopy referrals could also be interpreted as a proxy
for monetary costs. Our analysis highlights the important, but not
so often discussed, trade-offs in cervical cancer screening and
further explores how multiple outcomes can be assessed inde-
pendently in a single analysis. We provide decision makers with a
set of strategies that are efﬁcient with respect to total costs and
number of colposcopies, respectively. Moreover, we report the
required capacity for these strategies to be feasible. Finally, we
inform decision makers about the willingness to pay and accept
additional costs and harms needed in order for these strategies to
be optimal. For example, the most effective strategy was projected
Fig. 2 – Cost-effectiveness* (upper panel) and harm-beneﬁt† (lower panel) efﬁciency frontiers for the analysis of ages 25 to 33
years. Note. US $1 ¼ 6.35 NOK. CIN2þ, cervical intraepithelial lesion of grade 2 or more severe; NOK, Norwegian kroner. *In the
cost-effectiveness calculations, both costs (total US $ cost per screened woman) and effectiveness (total CIN2þ detected per
screened woman) are discounted by 4% per year. †In the harm-beneﬁt calculations, both harms (number of colposcopies w/
biopsies per 100,000 screened women) and beneﬁts (number of CIN2þ detected per 100,000 screened women) are
undiscounted. Strategies connected by the solid line represent the cost-effectiveness (upper panel) and harm-beneﬁt (lower
panel) efﬁciency frontier. (Color version of ﬁgure available online).
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case in Norway (baseline strategy), but, despite similar cost levels,
required 66% more colposcopies. For these strategies to be optimal,
capacity requirements must be met by the health sector, and
decision makers as well as individual women must be willing to
accept additional costs and colposcopies.
We found that harm-beneﬁt acceptability curves represent a
useful method for expressing harm-beneﬁt trade-offs explicitly,
while simultaneously incorporating uncertainty in the estimates.
The model can be used to assess the potential impact of various
screening strategies in terms of CIN2þ detection and the accom-
panying resource requirements. For decision makers worldwide
concerned with health care interventions, our analysis illustrates
how the cost-effectiveness framework can be used to quantify
and assess multiple trade-offs independently in a single analysis,while also considering capacity constraints. Moreover, decision
makers in other cervical cancer screening settings with similar
screening algorithms, diagnostic accuracy, and underlying risk of
CIN2þ may use the results of our study in their evaluation of
potential screening algorithms and the associated trade-offs
between beneﬁts and harms. In turn, the model can serve as a
tool for screen-eligible women to balance the screening trade-offs
according to their preferences for harms contingent to the
beneﬁts. Ultimately, by allowing women to decide which strategy
is optimal according to their willingness to accept additional
harms for additional beneﬁts, the harm-beneﬁt acceptability
curves introduce a potential framework for shared decision
making in screening follow-up. For instance, for the younger ages,
we projected that the guidelines in Norway until July 1, 2014 (i.e.,
baseline strategy), entailed 2.6 colposcopies per CIN2þ detected.
Table 3 – Cost-effectiveness (incremental costs per additional CIN2þ detected), harm-beneﬁt (incremental
colposcopy referrals per additional CIN2þ detected), and relative outcomes for ages 25–33 y.
Strategy§ Cost-effectiveness* Harm-beneﬁt† Relative outcomes‡
Total
cost
Total no.
of CIN2þ
detected
ICER Total no. of
colposcopies
w/biopsy
Total no.
of CIN2þ
detected
IHBR CIN2þ
detected
Total
costs
Colposcopies
w/biopsies
7 293.73 0.0126 – – – Ext. dom. 1.01 0.96
3 301.27 0.0166 1,921.80 – – Ext. dom. 1.32 0.99
6 – – Abs. dom 3,033.88 1,291.33 – 0.99 0.91
8 – – Abs. dom 3,154.09 1,332.32 2.93 1.02 0.94
4 – – Abs. dom 4,895.02 1,669.47 5.16 1.28 1.47
5 306.00 0.0170 11,550.22 5,540.31 1,728.61 10.91 1.36 1.00 1.66
Note. A strategy is strongly dominated if it is less effective and more costly than another strategy. A strategy is weakly dominated if the IHBR is
higher than that of the next, more effective strategy.
Abs., absolutely; CIN2þ, cervical intraepithelial neoplasia grade 2 or more severe; dom., dominated; ICER, incremental cost-effectiveness ratio;
IHBR, incremental harm-beneﬁt ratio (deﬁned as the number of additional colposcopy-directed biopsies required per additional CIN2þ
detected); Ext., extendedly.
* Results are presented per screened woman with both costs and effectiveness discounted by 4% per year.
† Results are presented per 100,000 screened woman with both outcomes undiscounted.
‡ Expresses relative outcomes (CIN2þ detection, total costs, and colposcopy use, for each strategy on the efﬁciency frontier compared with the
strategy used in Norway until July 1, 2014).
§ Includes strategies that were efﬁcient with respect to either efﬁciency metric.
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many colposcopies women are currently willing to accept to
achieve the current beneﬁts of screening. If this is the case, only
the resource-saving strategies (i.e., strategies 6 and 8) would be
considered optimal. With higher thresholds for willingness to
accept harms and costs, more alternative strategies become
available, with the baseline strategy as well as the recently
implemented strategy in Norway ranking among the most con-
servative, and therefore least effective in terms of CIN2þ detection.
Even though modeling provides a useful tool for quantifying
outcomes of multiple intervention strategies, a model is only as good
as its inputs and structure, and our model has several limitations.
Most importantly, the model predicts cancer precursors and not
invasive cancer. The aim of cervical cancer screening is not to detect
the most precursors, but to prevent the most cancers; thus, the
optimal strategy will depend on the extent to which cancer pre-
cursors progress to cancer or regress. We acknowledge the limitation
that our model does not use cancer as an endpoint, but rather uses
the surrogate endpoint of CIN2þ. Because CIN2þ is the treatment
threshold, it is an important endpoint that was speciﬁcally requested
by Norwegian decision makers. Although screening harms are a
composite of anxiety and pain, as well as time and travel costs
associated with physician consultations and screening procedures,
we chose the number of colposcopies as our primary outcome to
represent the harms of screening. We ﬁnd that the number of
colposcopies is a meaningful outcome in the analysis because
decision makers aim to keep the referral rates at an acceptable level,
both because of its cost-driving nature and because of the harms
caused to women. In the model, we accounted for loss-to-follow-up,
though it may be argued that noncompliance should not inﬂuence
which strategy is optimal and that dropout rates should be included
only in secondary analyses. Loss-to-follow-up, however, is a serious
concern in screening policy, and the effect of screening is likely
reduced because of inadequate follow-up of abnormal screening
results. In addition, imperfect screening coverage is also of concern
and limits the population effects of screening [53]. More than half of
the new cases of cervical cancer occur in womenwho have not had a
Papanicolaou test the last 3.5 years before diagnosis [54]. Conse-
quently, we found it important to take into account the impact of
compliance on screening outcomes, and thus we used up-to-date,
age- and referral-stratiﬁed dropout rates in Norway. Another aspectof our inputs relates to the modeling of positivity rates rather than
speciﬁcity. Modeling screening requires that one or the other be
determined endogenously, and both alternatives introduce potential
limitations. We chose to model positivity rates rather than the
speciﬁcity of a diagnostic test because we felt more conﬁdent in
the observed positivity rates, having observed that the speciﬁcity for
CIN2þ tends to vary with the prevalence [32,55]. Positivity rates,
however, may be dependent on the context of retrieval (e.g.,
characteristics of the study population), and the generalizability
from international studies to the Norwegian context may be limited.
Yet, modeling requires the use of best available, existing data, and can
be updated as new knowledge occurs.
Nevertheless, more research is needed to decide the optimal
combination of beneﬁts, harms, and resource use in cervical
cancer screening. In essence, enhanced knowledge of the pro-
gression and regression of cancer precursors given individual
screening record may contribute to achieve tailored individual
optimizations in terms of avoiding unnecessary procedures for
women with lesions likely to regress, and seamless workup of
women with lesions likely to progress. Moreover, there is a need
to acquire increased knowledge of women’s preferences regard-
ing the trade-off between reduced risk of cervical cancer and the
screening adverse effects, involving both short-term responses
such as anxiety and pain associated with screening procedures
and long-term consequences of treatment in terms of childbirth
complications. Knowing these preferences is crucial to underpin
the decision rule of how much society is willing to pay for
detecting an additional precancerous lesion, in terms of both
monetary costs and colposcopies performed, and, in turn, decid-
ing the optimal combination of beneﬁts, harms, and resource use.Conclusions
Screening for cervical cancer implies multiple trade-offs between
beneﬁts (preventing invasive cancer), harms (unnecessary proce-
dures), and resource use (e.g., monetary costs and physician
consultations). In Norway, it would be possible to detect more
cancer precursors at lower costs in terms of harms and resource
use. In general, however, more effective strategies also require
more colposcopies and monetary costs. Ideally, the choice of
Fig. 3 – Cost-effectiveness (upper panel) and harm-beneﬁt (lower panel) acceptability curve (CEAC/HBAC) for the analysis of
ages 25 to 33 years. The acceptability curves summarize the percentage of iterations a given strategy is “cost-effective” for a
given value of the decision rule (i.e., willingness to pay); in this case, the additional costs one is willing to pay for detecting an
additional CIN2þ (CEAC, upper panel), or the number of colposcopies one is willing to accept for detecting an additional CIN2þ
(HBAC, lower panel). CEAC, cost-effectiveness acceptability curve; CIN2þ, cervical intraepithelial neoplasia of grade 2 or more
severe; HBAC, harm-beneﬁt acceptability curve. (Color version of ﬁgure available online).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 8 8 – 1 0 9 7 1095strategy should be based on deﬁned efﬁciency measures, thor-
ough feasibility calculations, and ﬁnally, which strategy is opti-
mal should be based on society’s willingness to pay costs and
women’s willingness to accept harms.Acknowledgments
We are thankful for the contributions from Torbjørn Wisløff, Gry
Baadstrand Skare, and The Cancer Registry of Norway. We
appreciate constructive comments in response to presentations
given at the 2014 Asian, European and North-American Confer-
ence for the Society for Medical Decision Making.Source of ﬁnancial support: The lead author has received
ﬁnancial support by the Department of Health Management and
Health Economics at the University of Oslo, while no speciﬁc
funding has been sought for the coauthors.Supplemental materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2015.08.003 or, if a hard copy of article, at www.valueinhealth
journal.com/issues (select volume, issue, and article).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 8 8 – 1 0 9 71096R E F E R E N C E S
[1] Cantor SB, Fahs MC, Mandelblatt JS, et al. Decision science and cervical
cancer. Cancer 2003;98(Suppl.):2003–8.
[2] Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health
policy for cervical cancer prevention: the role of decision science,
economic evaluation, and mathematical modeling. Vaccine 2006;24
(Suppl. 3):S155–63.
[3] Cancer Registry of Norway. Cancer in Norway 2011—Cancer Incidence,
Mortality, Survival and Prevalence in Norway. Oslo: Cancer Registry of
Norway, 2013.
[4] Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell
carcinoma incidence in 13 European countries: changing risk and the
effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677–86.
[5] Peirson L, Fitzpatrick-Lewis D, Ciliska D, et al. Screening for cervical
cancer: a systematic review and meta-analysis. Syst Rev 2013;2:35.
[6] Vaccarella S, Franceschi S, Engholm G, et al. 50 years of screening in the
Nordic countries: quantifying the effects on cervical cancer incidence.
Br J Cancer 2014;111:965–9.
[7] Rogstad KE. The psychological impact of abnormal cytology and
colposcopy. BJOG 2002;109:364–8.
[8] Sharp L, Cotton S, Cruickshank M, et al. TOMBOLA Group. The
unintended consequences of cervical screening: distress in women
undergoing cytologic surveillance. J Low Genit Tract Dis 2014;18:142–50.
[9] Korfage IJ, Essink-Bot ML, Westenberg SM, et al. How distressing is
referral to colposcopy in cervical cancer screening? A prospective
quality of life study. Gynecol Oncol 2014;132:142–8.
[10] Sharp L, Cotton S, Cochran C, et al. After-effects reported by women
following colposcopy, cervical biopsies and LLETZ: results from the
TOMBOLA trial. BJOG 2009;116:1506–14.
[11] Albrechtsen S, Rasmussen S, Thoresen S, et al. Pregnancy outcome in
women before and after cervical conisation: population based cohort
study. BMJ 2008;337:a1343.
[12] Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes
after conservative treatment for intraepithelial or early invasive cervical
lesions: systematic review and meta-analysis. Lancet 2006;367:489–98.
[13] McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical
neoplasia and risk of invasive cancer in women with cervical
intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol
2008;9:425–34.
[14] Ofﬁcial Norwegian Guidelines in Gynecological Oncology. Norwegian
Society for Gynecology Obstetrics, Tromsø, Bergen, and Lørenskog,
Norway, 2009.
[15] Burger EA, Ortendahl JD, Sy S, et al. Cost-effectiveness of cervical
cancer screening with primary human papillomavirus testing in
Norway. Br J Cancer 2012;106:1571–8.
[16] Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al. Modeling human
papillomavirus and cervical cancer in the United States for analyses of
screening and vaccination. Popul Health Metr 2007;5:11.
[17] Siebert U, Sroczynski G, Hillemanns P, et al. The German cervical
cancer screening model: development and validation of a decision-
analytic model for cervical cancer screening in Germany. Eur J Public
Health 2006;16:185–92.
[18] Norwegian Directorate of Health. Economic evaluation of health
interventions—a guide. Available from: http://helsedirektoratet.no/
publikasjoner/okonomisk-evaluering-av-helsetiltak–en-veileder/
Publikasjoner/IS-1985.pdf. [Accessed September 15, 2014].
[19] Norwegian Ofﬁcial Report on Economic Evaluations. NOU 2012:16.
Available from: https://www.regjeringen.no/contentassets/5fce956d513
64811b8547eebdbcde52c/no/pdfs/nou201220120016000dddpdfs.pdf
[Accessed September 8, 2015].
[20] Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic
Evaluation. In: Gray A, Briggs A, Handbooks in Health Economic
Evaluation Series. New York, NY: Oxford University Press, 2006.
[21] Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and
validation: a report of the ISPOR-SMDM Modeling Good Research
Practices Task Force-7. Value Health 2012;15:843–50.
[22] TreeAge Pro 2014 User’s Manual. 2014. Available from: http://installers.
treeagesoftware.com/treeagepro/14.1.0/PDF/TP-Manual-2014R1.pdf.
[Accessed September 15, 2014].
[23] Norwegian Medical Association. Normal Tariff for Private General
Practice 2012–2013. Oslo, Norway, 2012.
[24] Cancer Registry of Norway. The Norwegian Cervical Cancer Screening
Program. The Cancer Registry of Norway, Oslo, Norway, 2011.
[25] Sorbye S, Arbyn M, Fismen S, et al. Triage of women with low-grade
cervical lesions–HPV mRNA testing versus repeat cytology. PLoS One
2011;6:e24083.
[26] Castle PE, Fetterman B, Thomas Cox J, et al. The age-speciﬁc
relationships of abnormal cytology and human papillomavirus DNA
results to the risk of cervical precancer and cancer. Obstet Gynecol
2010;116:76–84.[27] Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective
study of type-speciﬁc human papillomavirus infection and risk of
cervical neoplasia among 20,000 women in the Portland Kaiser Cohort
Study. Cancer Epidemiol Biomarkers Prev 2011;20:1398–409.
[28] Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial
of human papillomavirus (HPV) testing in primary cervical screening.
Health Technol Assess 2009;13:1–150: iii–iv.
[29] Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a
population-based randomized controlled trial for implementation of
high-risk HPV testing in cervical screening: design, methods and
baseline data of 44,102 women. Int J Cancer 2004;110:94–101.
[30] Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing
and liquid-based cytology: results at recruitment from the new
technologies for cervical cancer randomized controlled trial. J Natl
Cancer Inst 2006;98:765–74.
[31] Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing
and liquid-based cytology in primary screening of women younger
than 35 years: results at recruitment for a randomised controlled trial.
Lancet Oncol 2006;7:547–55.
[32] Cuzick J, Thomas Cox J, Zhang G, et al. Human papillomavirus testing
for triage of women with low-grade squamous intraepithelial lesions.
Int J Cancer 2013;132:959–66.
[33] Rijkaart DC, Berkhof J, van Kemanade FJ, et al. HPV DNA testing in
population-based cervical screening (VUSA-Screen study): results and
implications. Br J Cancer 2012;106:975–81.
[34] Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing
versus repeat cytology for triage of minor cytological cervical lesions.
Cochrane Database Syst Rev 2013;3:Cd008054.
[35] Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human
papillomavirus testing in secondary prevention of cervical cancer.
Vaccine 2012;30(Suppl. 5):F88–99.
[36] Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent
regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol
2009;113:18–25.
[37] Dalla Palma P, Giorgi Rossi P, Collina G, et al. The risk of false-positive
histology according to the reason for colposcopy referral in cervical
cancer screening: a blind revision of all histologic lesions found in the
NTCC trial. Am J Clin Pathol 2008;129:75–80.
[38] Discacciati MG, de Souza CA, d’Otavianno MG, et al. Outcome of
expectant management of cervical intraepithelial neoplasia grade 2 in
women followed for 12 months. Eur J Obstet Gynecol Reprod Biol
2011;155:204–8.
[39] Gheit T, Cornet I, Clifford GM, et al. Risks for persistence and
progression by human papillomavirus type 16 variant lineages among
a population-based sample of Danish women. Cancer Epidemiol
Biomarkers Prev 2011;20:1315–21.
[40] Goodman MT, Shvetsov YB, McDufﬁe K, et al. Prevalence, acquisition,
and clearance of cervical human papillomavirus infection among
women with normal cytology: Hawaii Human Papillomavirus Cohort
Study. Cancer Res 2008;68:8813–24.
[41] Guedes AC, Zeferino LC, Syrjanen KJ, et al. Short-term outcome of
cervical intraepithelial neoplasia grade 2: considerations for
management strategies and reproducibility of diagnosis. Anticancer
Res 2010;30:2319–23.
[42] Kim JW, Song S, Jin C, et al. Factors affecting the clearance of high-risk
human papillomavirus infection and the progression of cervical
intraepithelial neoplasia. J Int Med Res 2012;40:486–96.
[43] Nielsen A, Kjaer SK, Munk C, et al. Persistence of high-risk human
papillomavirus infection in a population-based cohort of Danish
women. J Med Virol 2010;82:616–23.
[44] Rosa MI, Fachel JM, Rosa DD, et al. Persistence and clearance of human
papillomavirus infection: a prospective cohort study. Am J Obstet
Gynecol 2008;199:617. e1–e7.
[45] Stoler MH, Vichnin MD, Ferenczy A, et al. The accuracy of colposcopic
biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int
J Cancer 2011;128:1354–62.
[46] Zuchna C, Hager M, Tringler B, et al. Diagnostic accuracy of guided
cervical biopsies: a prospective multicenter study comparing the
histopathology of simultaneous biopsy and cone specimen. Am J
Obstet Gynecol 2010;203:321. e1–e6.
[47] Pedersen K, Burger E, Lönnberg S, et al. Vedlegg 2: Kostnader og
kostnadseffektivitet ved innføring av HPV-test i primærscreening for
livmorhalskreft. 2013. Available from: http://www.helsedirektoratet.no/
helse-og-omsorgstjenester/kreft/screening/hpv-screening/
styringsgruppe/Documents/Kostnader%20og%20kostnadseffektivitet%
20ved%20innf%C3%B8ring%20av%20HPV-test%20i%20prim%C3%
A6rscreening%20for%20livmorhalskreft.pdf. [Accessed July 1, 2014].
[48] Norwegian Medical Association. Normal Tariff for Private General
Practice 2012–2013. Norwegian Medical Association, Oslo, Norway, 2012.
[49] Norwegian Medical Association. Normal Tariff for Private Specialist
Practice 2011-2012. Norwegian Medical Association, Oslo, Norway, 2012.
[50] Norwegian Directorate of Health. Activity-based funding 2013. 2013.
Available from: http://www.helsedirektoratet.no/ﬁnansiering/isf/
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 8 8 – 1 0 9 7 1097regelverket-for-isf/tidligere-regelverk/Documents/ISF_2013.pdf.
[Accessed April 14, 2014].
[51] Statistics Norway. 2012. Available from: http://www.ssb.no/english.
[Accessed September 1, 2013].
[52] Moger TA, Kristiansen IS. Direct and indirect costs of the Norwegian
Breast Cancer Screening Program. HEROWorking Paper 2012:3. Available
from: http://www.med.uio.no/helsam/forskning/nettverk/hero/
publikasjoner/skriftserie/2012/hero2012-3.pdf. [Accessed August 6, 2015].[53] Burger EA, Kim JJ. The value of improving failures within a cervical
cancer screening program: an example fromNorway. Int J Cancer 2014;135:
1931–9.
[54] Skare GB, Lönnberg S. Masseundersøkelsen mot livmorhalskreft.
Annual Report 2012. Oslo, Norway: Cancer Registry of Norway, 2014.
[55] Szarewski A, Mesher D, Cadman L, et al. Comparison of seven tests for
high-grade cervical intraepithelial neoplasia in women with abnormal
smears: the Predictors 2 study. J Clin Microbiol 2012;50:1867–73.
